Drug Type Monoclonal antibody, Enzyme |
Synonyms Pembrolizumab/MK-5180, Pembrolizumab/VX-869, MK 3475A + [4] |
Target |
Action modulators, inhibitors |
Mechanism Hyaluronic acid modulators, PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (19 Sep 2025), |
RegulationPriority Review (United States), Priority Review (China), Breakthrough Therapy (China), Orphan Drug (Japan) |


| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Advanced biliary tract cancer | China | 22 Sep 2026 | |
| Gastrooesophageal junction cancer | China | 22 Sep 2026 | |
| HER2 negative Gastric Cancer | China | 22 Sep 2026 | |
| HER2 negative Gastroesophageal Junction Adenocarcinoma | China | 22 Sep 2026 | |
| HER2 Positive Gastroesophageal Adenocarcinoma | China | 22 Sep 2026 | |
| HER2-positive gastric cancer | China | 22 Sep 2026 | |
| Locally Advanced Esophageal Squamous Cell Carcinoma | China | 22 Sep 2026 | |
| Locally Advanced Lung Non-Small Cell Carcinoma | China | 22 Sep 2026 | |
| Locally Advanced Urothelial Carcinoma | China | 22 Sep 2026 | |
| Metastatic Biliary Tract Carcinoma | China | 22 Sep 2026 | |
| Metastatic Esophageal Squamous Cell Carcinoma | China | 22 Sep 2026 | |
| Metastatic melanoma | China | 22 Sep 2026 | |
| metastatic non-small cell lung cancer | China | 22 Sep 2026 | |
| Metastatic Non-Squamous Non-Small Cell Lung Carcinoma | China | 22 Sep 2026 | |
| Metastatic urothelial carcinoma | China | 22 Sep 2026 | |
| MSI-H/dMMR Solid Tumors | China | 22 Sep 2026 | |
| PD-L1 positive Triple Negative Breast Cancer | China | 22 Sep 2026 | |
| Recurrent Squamous Cell Carcinoma of the Head and Neck | China | 22 Sep 2026 | |
| Resectable Lung Non-Small Cell Carcinoma | China | 22 Sep 2026 | |
| Squamous non-small cell lung cancer | China | 22 Sep 2026 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Muscle Invasive Bladder Carcinoma | NDA/BLA | United States | 23 Oct 2025 | |
| PD-L1 positive Non-Small Cell Lung Cancer | Phase 3 | United States | 21 Nov 2024 | |
| PD-L1 positive Non-Small Cell Lung Cancer | Phase 3 | Japan | 21 Nov 2024 | |
| PD-L1 positive Non-Small Cell Lung Cancer | Phase 3 | Germany | 21 Nov 2024 | |
| PD-L1 positive Non-Small Cell Lung Cancer | Phase 3 | Guatemala | 21 Nov 2024 | |
| PD-L1 positive Non-Small Cell Lung Cancer | Phase 3 | Peru | 21 Nov 2024 | |
| PD-L1 positive Non-Small Cell Lung Cancer | Phase 3 | Poland | 21 Nov 2024 | |
| PD-L1 positive Non-Small Cell Lung Cancer | Phase 3 | Romania | 21 Nov 2024 | |
| PD-L1 positive Non-Small Cell Lung Cancer | Phase 3 | South Korea | 21 Nov 2024 | |
| PD-L1 positive Non-Small Cell Lung Cancer | Phase 3 | Spain | 21 Nov 2024 |
Phase 2 | 147 | (Arm A: Pembrolizumab (+) Berahyaluronidase Alfa SC →Pembrolizumab IV) | yrskplepkv = wwsvkoylog qkzqljsttg (njwtpzcwnj, eocnkosqoq - fbnfwepmwp) View more | - | 08 Apr 2026 | ||
(Arm B: Pembrolizumab IV→Pembrolizumab (+) Berahyaluronidase Alfa SC) | yrskplepkv = hcqvpuzalm qkzqljsttg (njwtpzcwnj, mvherzbnaq - kabgycipkw) View more | ||||||
Phase 3 | 39 | Pegylated filgrastim+Filgrastim+Nab-paclitaxel+Pembrolizumab Formulated with Berahyaluronidase Alfa+Carboplatin+Pemetrexed+cisplatin (Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy) | zhalwtnogc = mfxzgichqu qcsydvadgq (viwiuizcbj, oausklpehz - hrjowgvrnv) View more | - | 12 Nov 2025 | ||
Nab-paclitaxel+Pegylated filgrastim+Carboplatin+Pemetrexed+Filgrastim+Paclitaxel+cisplatin+Pembrolizumab (Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy) | zhalwtnogc = lhsjxrobjv qcsydvadgq (viwiuizcbj, njzpfaacrx - pmrqzdhipc) View more | ||||||
Phase 3 | 377 | Nab-paclitaxel+Pembrolizumab Formulated with Berahyaluronidase Alfa+Pegylated filgrastim+Carboplatin+Pemetrexed+Filgrastim+cisplatin (Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy) | puxaovwsno(aqafxmohkn) = isqvzenvef qecddktqfa (kmibzwcedt, 40.41) View more | - | 28 Jul 2025 | ||
(Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy) | puxaovwsno(aqafxmohkn) = gfavoruhhc qecddktqfa (kmibzwcedt, 26.23) View more | ||||||
Phase 1 | 90 | Pembrolizumab with berahyaluronidase alfa (MK-3475A) | qcirznmgah(fhedveiguu) = jcuqibkhrg ekibtcjqon (fzgwxcfues, 562 - 2382) View more | - | 28 Apr 2025 | ||
Phase 3 | metastatic non-small cell lung cancer ROS1 Gene Mutation Negative | ALK Gene Mutation Negative | EGFR Gene Mutation Negative | 377 | Pembrolizumab SC 790 mg Q6W | gobatzxgcg(sxkqqalqol): Ratio = 1.14 (96% CI, 1.06 - 1.22) View more | Non-inferior | 27 Mar 2025 | |
Pembrolizumab IV 400 mg Q6W | |||||||
Phase 3 | metastatic non-small cell lung cancer First line | 378 | premftggni(xncswkljxq) = The Phase 3 trial met its dual primary pharmacokinetic (PK) endpoints. kabobuzaud (itfrrlpfpm ) | Non-inferior | 19 Nov 2024 | ||
intravenous pembrolizumab |






